Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Objectives To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications…

Read the full article here

Source: Annals of the Rheumatic Diseases

Categories: Latest Headlines, Rheumatology

Tags: covid19

Tweets with this article

Alfred Kim

PS Also, rheumatic disease patients on RTX do poorly: data from @rheum_covid revealed 4x higher odds of death in RTX users compared to methotrexate monotherapy once COVID-19 is contracted. So to me, nothing to lose with vaccinating these people. https://t.co/VrDVTh8fEJ

The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment

Age-related macular degeneration (AMD) is a progressive retinal disease and the major cause of irreversible vision loss in the elderly. Numerous studies have found both…

Alfred Kim March 26, 2024

Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies.

Thrombotic microangiopathies (TMA) are usually associated with hematological features (RH-TMA). The epidemiology of TMA limited to kidneys (RL-TMA) is unclear Therefore, patients with TMA and…

Alfred Kim March 11, 2024

Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins – PubMed

Effective inhibition of the complement system is needed to prevent the accelerated clearance of nanomaterials by complement cascade and inflammatory responses. Here we show that…

Alfred Kim December 1, 2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Background The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of…

ARD & RMD Open July 14, 2023

Related Articles